Adaptimmune Therapeutics
ADAP
$1.22
Share price
2.52%
Change (1 day)
-10.95%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) - Total assets
Total assets on the balance sheet as of December 2023 : $0.28 B
According to Adaptimmune Therapeutics's latest financial reports the company's total assets are $0.28 B. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Adaptimmune Therapeutics - Total assets on balance sheet (from 2014 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2023-12-31 | $0.28 B | -14.08% |
| 2022-12-31 | $0.32 B | -29.95% |
| 2021-12-31 | $0.46 B | 4.08% |
| 2020-12-31 | $0.45 B | 148.5% |
| 2019-12-31 | $0.18 B | -34.4% |
| 2018-12-31 | $0.27 B | -1.57% |
| 2017-12-31 | $0.28 B | 19.88% |
| 2016-12-31 | $0.23 B | |
| 2015-06-30 | $0.30 B | 441.54% |
| 2014-06-30 | $55.51 M | 2966.37% |
| 2013-06-30 | $1.81 M | -54.33% |
| 2012-06-30 | $3.96 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $0.83 B | 194.28% | 🇳🇱 Netherlands |
 Novavax NVAX | $1.79 B | 536.02% | 🇺🇸 USA |
 Exelixis EXEL | $2.94 B | 941.12% | 🇺🇸 USA |
 Enzo Biochem ENZ | $99.07 M | -64.94% | 🇺🇸 USA |